Erythropoietin requirements increase following hospitalization in end-stage renal disease patients

American Journal of Nephrology

Volumn 21, Issue 5, 2001, Pages 390-396

  Yaqub, Muhammad S ^a,b   Leiser, Jeffery ^a   Molitoris, Bruce A ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Nephrology Division   (United States)

Author keywords

Anemia; End stage renal disease; Erythropoietin; Hemodialysis; Hospitalization; Inflammation

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD TRANSFUSION; COMORBIDITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDICATION; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; KIDNEY FAILURE; KIDNEY SURGERY; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; SEX DIFFERENCE;

ANALYSIS OF VARIANCE; ANEMIA; BLOOD TRANSFUSION; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HOSPITALIZATION; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 0035743178     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046281     Document Type: Article

References (37)

1. Erythropoietin
2. Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells
3. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis
4. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial
5. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells
6. USA multicenter clinical trial with recombinant human eryrthropoietin
7. Factors affecting the response to erythropoietin in chronic renal failure
8. Resistance to recombinant human erythropoietin therapy: A real clinical entity
9. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously
10. Iron status in patients receiving erythropoietin for dialysis associated anemia
11. Analysis of initial resistance of erythropoiesis to treatment with recombinanat human erythropoietin
12. Occult infection and resistance of anaemia to rHuEPO therapy in renal failure
13. Inhibition of a response to erythropoietin in the presence of infection or malignancy
14. The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients
15. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia
16. Effect of aluminium overload on the bone marrow response to recombinant human erythropoietin
17. Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis
18. 12 levels after erythropoietin treatment
19. Resistance to erythropoietin: Immunohemolytic anemia induced by residual formaldehyde in dialyzers
20. rHuEpo-resistant anaemia in haemodialysis patients
21. Use of recombinant erythropoietin in thalassemic patients on dialysis
22. Effect of recombinant human erythropoietin on erythropoiesis in homozogous sickle-cell anaemia and renal failure
23. Clinical practice guidelines for anemia of chronic kidney disease: Update 2000
24. Hematocrits levels and hospitalization risks in hemodialysis patients
25. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients
26. Subcutaneous compared with intravenous Epotein in patients receiving hemodialysis
27. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia
28. Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialyzed patients
29. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients
30. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
31. Inhibition of erythropoietin production by cytokines: Implications for the anemia involved in inflammatory states
32. Progress in understanding the anemia of chronic disease
33. Pathogensis and treatment of the anemia of chronic disease
34. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients
35. Pathogenesis and treatment of the anemia of chronic disease
36. Epotein in the anemia of rheumatoid arthritis
37. R-HuEPO hyporesponsiveness - Who and why?